Society of Urologic Oncology Annual Meeting (SUO) | Conference

Adam J. Gadzinski, MD, MS, on Up-and-Coming Research for Urologic Oncology
January 07, 2021

The expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.

Ramaprasad Srinivasan, MD, PhD, on Next Steps for MK-6482 in VHL-Associated Disease
December 29, 2020

Study results indicated that the small molecule HIF-2α inhibitor MK-6482 induced positive results in patients with certain Von Hippel-Lindau disease–associated solid tumors.

Adam J. Gadzinski, MD, MS, on Study Results Assessing the Impact of Telemedicine on Patient-Reported Outcomes
December 21, 2020

The study was designed to determine the impact of a rurally focused telemedicine program on patient outcomes.

Vikram Narayan, MD, Discusses Nadofaragene, Anti-Adenovirus Antibodies and Cystectomy for Patients with NMIBC
December 21, 2020

Narayan expanded on the other studies he contributed to from SUO investigating nadofaragene for patients with NMIBC.

Vikram M. Narayan, MD, on Nadofaragene Firadenovec Efficacy Across Different Patient Subgroups for NMIBC
December 16, 2020

At the 2020 SUO Meeting, Vikram M. Narayan, MD, spoke about the preliminary finds of his work with nadofaragene firadenovec.

Pouch Diversion May Lead to Decision Regret in Patients Undergoing Cystectomy
December 07, 2020

Patients who underwent pouch diversion reported significantly more regret than patients undergoing neobladder or ileal conduit.

Jelmyto Induces Durable Responses in Low-Grade UTUC
December 06, 2020

Data for a key study secondary outcome measure showed that 56.1% of patients who achieved a complete response to Jelmyto maintained that response at 12 months.

Study Identifies Prevalence of Germline Mutations Associated with RCC
December 05, 2020

Researchers identified the prevalence of germline mutations associated with the early-onset renal cell carcinoma, as well as clinicopathologic factors linked to an increased risk of carrying these mutations.

MK-6482 Demonstrates Durable Efficacy For VHL-Associated Clear Cell RCC
December 05, 2020

A phase 2 study found that the investigational HIF-2α inhibitor MK-6482 has durable efficacy in patients with Von Hippel-Lindau associated clear cell renal cell carcinoma and non-renal lesions.

Role of Biomarkers in Selection of Patients with Prostate Cancer for Focal Therapy Currently Unclear
December 05, 2020

A clear and reliable biomarker to select patients with prostate cancer for active surveillance or focal therapy has not yet been determined but inferring a course of action from existing biomarkers may be possible.